novo nordisk glp-1 receptor agonist weight management diabetes treatments agonists are increasingly used to treat type 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Novo Nordisk's Wegovy is First

Legal Status of IGFDES: Is It Safe and Allowed

reported that Shaoyao-Gancao Decoction (SGD), commonly used to treat multiple gynecological disorders such as dysmenorrhea, adenomyosis, and PCOS, modulated gut microbiota composition, and alleviated chronic low-grade inflammation by downregulating cytokines including IL-18, IL-1, IL-6, and TNF- in both serum and ovarian mRNA expression in PCOS rats (238)

**[Retatrutide](/products/retatrutide-001)** Triple-agonist peptide with the highest recorded fat loss (~24%) of any weight loss peptide

The ameliorating effect of limosilactobacillus fermentum and its supernatant postbiotic on cisplatin-induced chronic kidney disease in an animal model

Users who continue aggravating activities during treatment often see minimal benefit